Concentra (CON) Q1 2026 earnings review
Broad-Based Growth Drives Beat and Raise
Concentra continues to execute flawlessly on its dual organic and inorganic growth strategy. Q1 revenue grew 13.7% YoY, driving a 17.6% increase in Adjusted EBITDA and 69 bps of margin expansion despite ongoing public company transition costs. The integration of Nova and Pivot Onsite Innovations is clearly paying off, pushing total daily visits up 6.7%. Most impressively, core workers' compensation volumes showed robust organic acceleration (+6.2%). Management's confidence in the business trajectory is reflected in across-the-board guidance hikes and steady deleveraging during its seasonally weakest cash flow quarter.
🐂 Bull Case
Adjusted EBITDA margins expanded by 69 bps YoY to 21.2%. The company is realizing operational leverage from rate increases (+3.1% revenue per visit) and realizing M&A cost synergies, offsetting incremental public company expenses.
Workers' Compensation visits per day grew 9.6% YoY, with organic growth accelerating to a stellar 6.2%. This outpaces broader macro labor trends and demonstrates tangible market share gains.
🐻 Bear Case
Employer Services organic visit growth slowed to just 0.7% YoY in Q1. Following a much-touted 'turnaround' narrative in 2025, this deceleration warrants monitoring amid broader macroeconomic hiring caution.
Consumer Health visits plummeted 9.4% YoY. While it represents less than 2% of total visits, it marks a significant reversal in a segment that previously provided supplemental high-margin volume.
⚖️ Verdict: 🟢
Bullish. The company is delivering on every promise made since its IPO: expanding margins, seamlessly integrating major acquisitions, and organically taking market share in its core Workers' Comp business. The raised guidance is well-supported by underlying operational momentum.
Key Themes
Workers' Compensation Core Acceleration
The Workers' Compensation segment remains the primary growth engine. Total visits per day increased 9.6% YoY to 25,132. Crucially, excluding the impact of the Nova acquisition, organic growth was 6.2%—a significant acceleration that proves Concentra is taking market share regardless of the broader BLS labor market data.
Onsite Health Clinics Scale Advantage
Following the Pivot acquisition, Concentra's Onsite Health Clinic footprint has exploded from 160 clinics in Q1 2025 to 411 clinics today. Segment revenue surged 124.7% YoY to $37.2M. This provides a massive platform to upsell advanced primary care services directly to employers, creating a sticky, recurring revenue stream.
Deleveraging Trajectory on Target
Management executed perfectly on its balance sheet promises. Despite Q1 being the seasonally weakest cash flow quarter, the Net Leverage Ratio held steady sequentially at 3.4x, down dramatically from 3.9x a year ago. The company remains squarely on track to hit its sub-3.0x target by year-end 2026, which will unlock capacity for the next wave of M&A.
Employer Services Organic Deceleration
While total Employer Services visits grew 4.8% YoY, organic growth (excluding M&A) was a meager +0.7%. In previous quarters, management hailed the 'inflection' of this segment as a major catalyst. A drop back below 1% organic growth suggests employers are slowing down pre-employment screenings and broader hiring initiatives.
Consumer Health Volume Reversing
Consumer health visits per day reversed sharply, declining 9.4% YoY to just 907. While this segment is small, it has historically commanded solid revenue per visit ($136.97 in Q1). Management needs to clarify if this is an intentional strategic shift away from consumer urgent care, or a failure to compete for retail walk-in traffic.
Other KPIs
Reversing from -$4.0 million in the prior year quarter. Q1 is historically the slowest quarter for FCF due to bonus payouts, working capital seasonality, and interest payments. Printing a positive number here strongly underpins the raised full-year guidance of $215M-$235M.
Decreased 29.5% YoY from $15.7 million. This drop reflects the conclusion of one-time transition and rebranding expenditures associated with the 2025 Nova and Pivot acquisitions, paving the way for higher free cash flow conversion throughout the remainder of 2026.
The company actively bought back 661,000 shares at a weighted average price of $22.68. This demonstrates management's confidence in the valuation and showcases their ability to simultaneously deleverage, invest in de novos, and return capital to shareholders.
Guidance
Stable. Raised from the previous $2.250 - $2.350 billion range. The midpoint of $2.325B implies roughly 7.5% YoY growth over FY25's $2.163B, supported by low single-digit visit growth, ~3% rate growth, and a full-year contribution from recent acquisitions.
Accelerating. Raised from the previous $450 - $470 million range. The midpoint of $470M implies 8.8% YoY growth, indicating that management expects operating leverage and synergy capture to outpace top-line growth, driving further margin expansion.
Accelerating. Raised from the prior $200 - $225 million guide. The midpoint implies a strong 13.7% YoY increase from FY25's $197.8M, benefiting from the roll-off of acquisition integration costs and structurally lower CapEx.
Stable. The company maintained its target to end the year below 3.0x. Exiting Q1 at 3.4x makes this highly achievable given the back-half weighting of the company's cash flow generation.
Key Questions
Employer Services Organic Outlook
Organic visit growth in Employer Services slowed to 0.7% this quarter. Are you seeing specific pockets of hiring weakness among your corporate clients, and how are you forecasting organic volume for this segment in the back half of the year?
Consumer Health Declines
Consumer health visits dropped over 9% year-over-year. Is this an intentional strategic deprioritization of urgent care to focus purely on B2B occupational health, or a symptom of increased retail competition?
M&A Strategy Post-Deleveraging
With net leverage tracking comfortably toward your sub-3.0x target by year-end, how should we think about the M&A pipeline going into 2027? Will you resume larger platform acquisitions, or stick strictly to 1-5 center bolt-ons?